Novo Nordisk A/S (NVO) Traded Lower Due To Investor Disappointment Over Its New Drug In Obesity
Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...
Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
The Pharma Letter6d
The week in pharma: action, reaction and insight – week to March 14
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
Will Trump’s tariffs turbocharge foreign investment in America?
For Global companies, there is no place quite like America. As growth in China and Europe has slowed, its economy has ...
Trump’s anti-DEI dictates have global companies quietly strategizing to preserve autonomy
Boardrooms are under increasing pressure - from lawyers as well as staff - to work out how to tread the DEI tightrope.
Fierce Biotech2d
'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...
Eli Lilly Launches Weight-Loss Drug Mounjaro in India, Beats Novo Nordisk to Major Market
HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating ...